哮喘联盟

   摘要
   过敏原特异性免疫治疗（AIT）被认为是唯一能够改变过敏性呼吸系统疾病自然病程的治疗方法。与AIT相关的可能不良事件，到现在为止，限制了它在轻度哮喘以及得到控制的哮喘中的应用。AIT预给药或AIT和奥马珠单抗（一种抗IgE的人源化抗体）联合给药，被推荐用于治疗重症过敏性哮喘，对于减少由AIT导致的不良事件是有用的，并允许其在更严重的哮喘患者或未能控制的哮喘患者身上使用。有几个试验研究了AIT / 奥玛珠单抗联合用药在哮喘患者以及其他过敏性疾病，如鼻炎、膜翅目系统反应和食物过敏中的疗效，且取得了有意义的结果。我们正处于一个新时代的开始：以表型/基因型为基础的治疗将与 药物治疗和/或非药理学表型/基因型驱动的治疗相联系，以优化疾病控制和/或使其他治疗方法更安全。
 

  （杨冬 审校）
Expert Rev Respir Med. 2015 Jan 12:1-6. [Epub ahead of print]


 

The relationship between allergen immunotherapy and omalizumab for treating asthma.
 

Braido F1, Corsico A, Rogkakou A, Ronzoni V, Baiardini I, Canonica GW.
 

Abstract
Allergen-specific immunotherapy (AIT) is considered the only treatment capable of modifying the natural history of allergic respiratory disorders. The possible adverse events related to AIT have, until now, limited its use to mild and controlled asthma. The pre-administration or concomitant treatment of AIT and omalizumab (an anti-IgE humanized antibody), recommended for the treatment of severe allergic asthma, could be useful in reducing the adverse events due to AIT and to allow its use in patients with more severe or uncontrolled asthma. AIT/omalizumab combination has been explored in a few trials on asthma patients and also in other allergic disorders, such as rhinitis, hymenoptera systemic reaction and food allergy with significant results. We are at the beginning a new era where phenotype/endotype-based treatment will be associated with drug mass therapy and/or nonpharmacological phenotype/endotype-driven treatment to optimize disease control and/or to make the use of other treatments safer.
 

Expert Rev Respir Med. 2015 Jan 12:1-6. [Epub ahead of print]